Kidney Transplant | Current Treatment | US | 2019
Each year in the United States, thousands of patients suffering from end-stage renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. However, these powerful agents come with considerable risks on top of their important benefits. This report explores the differences in prescribing practices, attitudes, and perceptions of the general nephrologists, transplant nephrologists, and transplant surgeons involved in kidney patients’ continuum of care and uncovers potential opportunities in the marketing of current and future immunosuppressant therapies.
QUESTIONS ANSWERED
- What are the key drug classes used for induction and maintenance immunosuppressive regimens in kidney transplant patients?
- How do prescribers adjust induction and maintenance regimens if patients are not responding adequately?
- What are the key drivers and constraints of prescribing the most popular branded agents?
- What are prescribers’ estimates regarding patients’ compliance with current therapies?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
